Kadmon Holdings, Inc. - Special Call
Llamada en conferencia Kadmon Holdings Inc
Kadmon Holdings Inc Conference call will be held on 13-feb-2018. During the earnings conference call's session Kadmon Holdings Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Kadmon Holdings Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our research and clinical development team members, who prior to joining Kadmon brought more than 15 drugs to market, to identify and develop our novel product candidates, through inlicensing products and employing our small molecule and biologics platforms. By retaining global commercial rights to our clinical product candidates, we believe we have the ability to progress these candidates ourselves while maintaining flexibility for commercial and licensing arrangements. Below is a brief description of our lead product candidates: · KD025. The most advanced candidate in our rho-associated coiled-coil kinase (ROCK) platform, KD025, is a potential first-in-class, oral, selective ROCK2 inhibitor.Leer más Llamada en conferencia